Literature DB >> 23916477

Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models.

Wenjiao Tai1, Xuan Ye1, Xiuqi Bao1, Baozhong Zhao2, Xiaoliang Wang1, Dan Zhang3.   

Abstract

The participation of neuroinflammation in the pathogenesis of Parkinson's disease (PD) has long been validated. Excessive activated microglia release a large number of pro-inflammatory factors, damage surrounding neurons and eventually induce neurodegeneration. Inhibition of microglial over-activation might be a promising strategy for PD treatment. FLZ (formulated as: N-(2-(4-hydroxy-phenyl)-ethyl)-2-(2, 5-dimethoxy-phenyl)-3-(3-methoxy-4-hydroxy-phenyl)-acrylamide, the code name: FLZ), a natural squamosamide derivative from a Chinese herb, has been shown to inhibit over-activated microglia and protect dopaminergic neurons in previous studies, but the mechanism remains unclear. In the present study, we further investigated the mechanism in lipopolysaccharide (LPS)-induced in vivo and in vitro PD models. FLZ treatment significantly improved the motor dysfunction of PD model rats induced by intra-nigral injection of LPS and this beneficial effect of FLZ attributed to the inhibition of microglial over-activation and the protection on dopaminergic neurons in the substantia nigra (SN). In vitro mechanistic study revealed that the inhibitive effect of FLZ on microglia was mediated by suppressing Src kinase related inflammatory signaling pathway activation and subsequent NF-κBp65 nuclear translocation, inhibiting nitric oxide (NO) and reactive oxygen species (ROS) production, decreasing nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation. In conclusion, the present study supports that FLZ exerts neuroprotection against LPS-induced dopaminergic neurodegeneration through its anti-inflammatory effect, which is mediated by suppressing Src tyrosine kinase and the downstream inflammatory signaling pathway. Furthermore, this study defines a critical role of Src tyrosine kinase in neuroinflammation, and suggests that particular tyrosine kinase inhibition may be a potential anti-inflammatory approach for PD treatment.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DA; DOPAC; HVA; Iba-1; LPS; NADPH; NADPH oxidase; NF-κB; NO; Neuroinflammation; ORP; PD; PI3K; Parkinson's disease; ROS; SN; Src tyrosine kinase; TH; TLRs; dihydroxyphenylacetic acid; dopamine; homovanillic acid; ionized calcium binding adaptor molecule-1; lipopolysaccharide; nicotinamide adenine dinucleotide phosphate; nitric oxide; nuclear factor κB; overall rod performance; phosphorylated phosphoinositide 3-kinase; reactive oxygen species; substantia nigra; toll-like receptors; tyrosine hydroxylase

Mesh:

Substances:

Year:  2013        PMID: 23916477     DOI: 10.1016/j.neuropharm.2013.07.020

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  16 in total

1.  Biochanin A Protects Against Lipopolysaccharide-Induced Damage of Dopaminergic Neurons Both In Vivo and In Vitro via Inhibition of Microglial Activation.

Authors:  Jun Wang; Wang-Yang Wu; Huan Huang; Wei-Zu Li; Han-Qing Chen; Yan-Yan Yin
Journal:  Neurotox Res       Date:  2016-07-14       Impact factor: 3.911

2.  Up-Regulation of Corticocerebral NKD2 in Lipopolysaccharide-Induced Neuroinflammation.

Authors:  Zhiming Cui; Li Zhou; Yan Song; Chun Liu; Guanghui Zhu; Xinmin Wu; Yaohua Yan; Xiaopeng Xia; Chengwei Duan; Ying Zhou; Yuejiao Huang; Dongmei Zhang
Journal:  Cell Mol Neurobiol       Date:  2015-06-18       Impact factor: 5.046

3.  Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson's disease models are mediated by GPR109A-dependent mechanisms.

Authors:  Shou-Peng Fu; Jian-Fa Wang; Wen-Jing Xue; Hong-Mei Liu; Bing-run Liu; Ya-Long Zeng; Su-Nan Li; Bing-Xu Huang; Qing-Kang Lv; Wei Wang; Ju-Xiong Liu
Journal:  J Neuroinflammation       Date:  2015-01-17       Impact factor: 8.322

4.  GLP-2 Attenuates LPS-Induced Inflammation in BV-2 Cells by Inhibiting ERK1/2, JNK1/2 and NF-κB Signaling Pathways.

Authors:  Nan Li; Bo-Wen Liu; Wen-Zhi Ren; Ju-Xiong Liu; Su-Nan Li; Shou-Peng Fu; Ya-Long Zeng; Shi-Yao Xu; Xuan Yan; Ying-Jie Gao; Dian-Feng Liu; Wei Wang
Journal:  Int J Mol Sci       Date:  2016-02-04       Impact factor: 5.923

5.  Galangin Reduces the Loss of Dopaminergic Neurons in an LPS-Evoked Model of Parkinson's Disease in Rats.

Authors:  Guangxin Chen; Juxiong Liu; Liqiang Jiang; Xin Ran; Dewei He; Yuhang Li; Bingxu Huang; Wei Wang; Shoupeng Fu
Journal:  Int J Mol Sci       Date:  2017-12-21       Impact factor: 5.923

6.  A c-Src Inhibitor Peptide Based on Connexin43 Exerts Neuroprotective Effects through the Inhibition of Glial Hemichannel Activity.

Authors:  Ester Gangoso; Rocío Talaverón; Myriam Jaraíz-Rodríguez; Marta Domínguez-Prieto; Pascal Ezan; Annette Koulakoff; José M Medina; Christian Giaume; Arantxa Tabernero
Journal:  Front Mol Neurosci       Date:  2017-12-15       Impact factor: 5.639

7.  Vanillin Protects Dopaminergic Neurons against Inflammation-Mediated Cell Death by Inhibiting ERK1/2, P38 and the NF-κB Signaling Pathway.

Authors:  Xuan Yan; Dian-Feng Liu; Xiang-Yang Zhang; Dong Liu; Shi-Yao Xu; Guang-Xin Chen; Bing-Xu Huang; Wen-Zhi Ren; Wei Wang; Shou-Peng Fu; Ju-Xiong Liu
Journal:  Int J Mol Sci       Date:  2017-02-12       Impact factor: 5.923

8.  Alkaloids from piper longum protect dopaminergic neurons against inflammation-mediated damage induced by intranigral injection of lipopolysaccharide.

Authors:  Huan He; Wei-Wei Guo; Rong-Rong Xu; Xiao-Qing Chen; Nan Zhang; Xia Wu; Xiao-Min Wang
Journal:  BMC Complement Altern Med       Date:  2016-10-24       Impact factor: 3.659

9.  Peiminine Protects Dopaminergic Neurons from Inflammation-Induced Cell Death by Inhibiting the ERK1/2 and NF-κB Signalling Pathways.

Authors:  Guangxin Chen; Juxiong Liu; Liqiang Jiang; Xin Ran; Dewei He; Yuhang Li; Bingxu Huang; Wei Wang; Dianfeng Liu; Shoupeng Fu
Journal:  Int J Mol Sci       Date:  2018-03-12       Impact factor: 5.923

10.  Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson's disease treatment.

Authors:  Junmei Shang; Shurong Ma; Caixia Zang; Xiuqi Bao; Yan Wang; Dan Zhang
Journal:  Acta Pharm Sin B       Date:  2021-01-26       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.